PL1765396T3 - Przeciwciała przeciwko PSGL-1 - Google Patents

Przeciwciała przeciwko PSGL-1

Info

Publication number
PL1765396T3
PL1765396T3 PL05747985T PL05747985T PL1765396T3 PL 1765396 T3 PL1765396 T3 PL 1765396T3 PL 05747985 T PL05747985 T PL 05747985T PL 05747985 T PL05747985 T PL 05747985T PL 1765396 T3 PL1765396 T3 PL 1765396T3
Authority
PL
Poland
Prior art keywords
psgl
antibodies
Prior art date
Application number
PL05747985T
Other languages
English (en)
Inventor
Rong-Hwa Lin
Chung Nan Chang
Pei-Jiun Chen
Chiu-Chen Huang
Original Assignee
Abgenomics Cooeperatief U A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35394680&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1765396(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abgenomics Cooeperatief U A filed Critical Abgenomics Cooeperatief U A
Publication of PL1765396T3 publication Critical patent/PL1765396T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Plant Pathology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL05747985T 2004-05-10 2005-05-10 Przeciwciała przeciwko PSGL-1 PL1765396T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56989204P 2004-05-10 2004-05-10
PCT/US2005/016357 WO2005110475A2 (en) 2004-05-10 2005-05-10 Antibodies
EP05747985.9A EP1765396B1 (en) 2004-05-10 2005-05-10 Anti-psgl-1 antibodies

Publications (1)

Publication Number Publication Date
PL1765396T3 true PL1765396T3 (pl) 2014-07-31

Family

ID=35394680

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05747985T PL1765396T3 (pl) 2004-05-10 2005-05-10 Przeciwciała przeciwko PSGL-1

Country Status (27)

Country Link
US (8) US7604800B2 (pl)
EP (3) EP1765396B1 (pl)
JP (4) JP5623690B2 (pl)
KR (1) KR101256400B1 (pl)
CN (2) CN1984680B (pl)
AR (1) AR048781A1 (pl)
AU (1) AU2005244072C1 (pl)
BR (1) BRPI0510567B8 (pl)
CA (3) CA2566305C (pl)
DK (1) DK1765396T3 (pl)
EC (1) ECSP067056A (pl)
EG (1) EG26781A (pl)
ES (3) ES2602633T3 (pl)
IL (3) IL178838A (pl)
MX (1) MXPA06012986A (pl)
MY (1) MY148646A (pl)
NO (1) NO341844B1 (pl)
NZ (3) NZ551626A (pl)
PH (1) PH12015500247A1 (pl)
PL (1) PL1765396T3 (pl)
PT (1) PT1765396E (pl)
RU (1) RU2482131C2 (pl)
SG (2) SG10201606541UA (pl)
TW (2) TWI402274B (pl)
UA (1) UA100356C2 (pl)
UY (1) UY28886A1 (pl)
WO (1) WO2005110475A2 (pl)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040116333A1 (en) 2001-08-03 2004-06-17 Rong-Hwa Lin Modulators of P-selectin glycoprotein ligand 1
US7744888B2 (en) 2001-08-03 2010-06-29 Abgenomics Cooperatief U.A. Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies
MY148646A (en) * 2004-05-10 2013-05-15 Abgenomics Cooperatief Ua Anti-psgl-1 antibodies
WO2005110456A2 (en) * 2004-05-11 2005-11-24 Abgenomics Corporation T-cell death-inducing epitopes
WO2007067984A2 (en) * 2005-12-09 2007-06-14 Wyeth Neutralizing antibodies against primate psgl-1 and uses therefor
US8722856B2 (en) * 2008-10-28 2014-05-13 National University Corporation Hokkaido University Anti-MUC1 antibody
TWI606520B (zh) * 2008-10-31 2017-11-21 半導體能源研究所股份有限公司 半導體裝置及其製造方法
GB0822011D0 (en) * 2008-12-02 2009-01-07 Queen Mary & Westfield College Treatment
RU2595409C2 (ru) 2009-09-03 2016-08-27 Мерк Шарп И Доум Корп., Анти-gitr-антитела
US8889132B2 (en) 2010-06-30 2014-11-18 Mount Sinai Hospital Antibodies against human HIF-1α
ES2387156B1 (es) * 2010-12-01 2013-07-04 Universidad Autónoma de Madrid Uso de psgl-1 para el tratamiento de enfermedades inflamatorias y autoinmunes
US20130209449A9 (en) * 2011-06-13 2013-08-15 Abgenomics Cooperatief U.A. Anti-psgl-1 antibodies and uses thereof
WO2013057092A1 (en) 2011-10-17 2013-04-25 Westfaelische Wilhelms-Universitaet Muenster Methods of risk assessment of pml and related apparatus
AU2013306390B2 (en) 2012-08-24 2018-07-05 The Regents Of The University Of California Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis
TWI595007B (zh) * 2012-09-10 2017-08-11 Neotope Biosciences Ltd 抗ｍｃａｍ抗體及相關使用方法
US10988528B2 (en) * 2015-08-13 2021-04-27 New York University Antibody-based molecules specific for the truncated ASP421 epitope of Tau and their uses in the diagnosis and treatment of tauopathy
CN108713026B (zh) * 2016-01-08 2023-01-06 美国全心医药生技股份有限公司 四价抗psgl-1抗体及其用途
WO2017214941A1 (zh) * 2016-06-16 2017-12-21 毛侃琅 一种提升SelP基因表达水平的慢病毒载体及其应用
CN109996544A (zh) 2016-06-27 2019-07-09 加利福尼亚大学董事会 癌症治疗组合
CN111201038A (zh) * 2017-01-11 2020-05-26 戊瑞治疗有限公司 Psgl-1拮抗剂及其用途
CA3054067A1 (en) 2017-03-14 2018-09-20 Five Prime Therapeutics, Inc. Antibodies binding to vista at acidic ph
TW201945393A (zh) 2018-03-21 2019-12-01 美商戊瑞治療有限公司 在酸性pH結合至VISTA之抗體
CN121203021A (zh) 2018-07-11 2025-12-26 戊瑞治疗有限公司 在酸性pH下结合至VISTA的抗体
IL280199B2 (en) 2018-07-20 2025-08-01 Pf Medicament Receptor for vista
TW202110891A (zh) * 2019-06-04 2021-03-16 美商維西歐製藥公司 抗psgl-1組合物及其用於調節骨髓細胞發炎表型之方法及用途
EP4094779A4 (en) * 2020-01-22 2023-11-22 Shanghai Senhui Medicine Co., Ltd. ACTIVE CONJUGATE OF ERIBULIN DERIVATIVE, METHOD FOR THE PRODUCTION THEREOF AND ITS USE IN MEDICINE
KR20240107151A (ko) * 2021-11-17 2024-07-08 알트루바이오 인코퍼레이티드 T-세포 매개 염증 질환 또는 암을 치료하기 위해 jak 억제제와 조합하여 항-psgl-1 항체를 사용하는 방법
TW202540180A (zh) * 2023-11-17 2025-10-16 美商美國全心醫藥生技股份有限公司 抗psgl-1抗體及其用途

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5464778A (en) 1989-03-08 1995-11-07 Board Of Regents Of The University Of Oklahoma Glycoprotein ligand for P-selectin and methods of use thereof
US5378464A (en) * 1989-03-08 1995-01-03 Board Of Regents Of The University Of Oklahoma Modulation of inflammatory responses by administration of GMP-140 or antibody to GMP-140
US5690933A (en) * 1989-05-31 1997-11-25 Glaxo Wellcome Inc. Monoclonal antibodies for inducing tolerance
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DE69127627T2 (de) 1990-08-29 1998-02-19 Genpharm Int Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper
US5709859A (en) * 1991-01-24 1998-01-20 Bristol-Myers Squibb Company Mixed specificity fusion proteins
US6124267A (en) * 1991-02-05 2000-09-26 Southpac Trust Internationals, Inc. O-glycan inhibitors of selectin mediated inflammation derived from PSGL-1
US6309639B1 (en) 1991-02-05 2001-10-30 The Board Of Regents Of The University Of Oklahoma Method for inhibiting an inflammatory response using antibodies to P-selectin glycoprotein ligand
US5972625A (en) * 1991-05-06 1999-10-26 The Regents Of The University Of California Assays for inhibitors of leukocyte adhesion
US5866124A (en) * 1992-03-17 1999-02-02 Novartis Corporation Antiidiotypic antibodies for high molecular weight-melanoma associated antigen
US5843707A (en) * 1992-10-23 1998-12-01 Genetics Institute, Inc. Nucleic acid encoding a novel P-selectin ligand protein
US6210671B1 (en) 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
KR100371784B1 (ko) * 1992-12-01 2003-07-22 프로테인 디자인랩스, 인코포레이티드 L-셀렉틴과반응성인인체화된항체
US5710123A (en) * 1992-12-18 1998-01-20 Centocor, Inc. Peptide inhibitors of selectin binding
EP0689599B1 (en) * 1993-01-25 1998-12-09 Dana-Farber Cancer Institute, Inc. Chimeric selectins by exchange of domains - uses thereof
HUT75894A (en) * 1993-05-05 1997-05-28 Cytel Corp Antibodies to p-selectin and their uses
WO1995014787A1 (en) * 1993-11-22 1995-06-01 Centocor, Inc. Peptide inhibitors of selecting binding
DE69630307T2 (de) 1995-08-03 2004-07-15 The Board Of Regents Of The University Of Oklahoma, Norman O-glycaninhibitoren von selectinvermittelten entzüngen
US6348581B1 (en) * 1996-10-31 2002-02-19 The Dow Chemical Company High affinity humanized anti-TAG-72 monoclonalantibodies
JP3248570B2 (ja) * 1997-10-09 2002-01-21 日本電気株式会社 半導体装置の製造方法
WO1999043353A2 (en) * 1998-02-26 1999-09-02 Boehringer Ingelheim Pharmaceuticals, Inc. Combination anti-selectin and immunosuppressant therapy
IL142717A0 (en) 1998-10-30 2002-03-10 Genetics Inst Inhibition of differentiation of cytotoxic t-cells by p-selectin ligand (psgl) antagonists
US6696620B2 (en) 2000-05-02 2004-02-24 Epicyte Pharmaceutical, Inc. Immunoglobulin binding protein arrays in eukaryotic cells
AU2001261735B2 (en) * 2000-05-19 2006-09-21 The Center For Blood Research, Inc. Methods for diagnosing and treating hemostatic disorders by modulating p-selectin activity
CN1124928C (zh) * 2000-07-11 2003-10-22 湛江包装材料企业有限公司 光降解双向拉伸聚丙烯薄膜的制造方法
EP1325123A4 (en) * 2000-09-12 2004-07-21 Inst Genetics Llc STENOSE- OR RESEARCH INHIBITION BY P-SELECTIN ANTAGONISTS
US20040002450A1 (en) * 2000-12-29 2004-01-01 Janette Lazarovits Y17 - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US20040001839A1 (en) * 2000-12-29 2004-01-01 Avigdor Levanon Multimers - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
CZ20031982A3 (cs) 2000-12-29 2004-09-15 Bio-Technology General Corp. Izolované molekuly zahrnující epitopy obsahující sulfatované sloučeniny, protilátky proti takovým epitopům a jejich použití
US6884619B2 (en) * 2001-07-17 2005-04-26 Yale University Inhibition of BEHAB cleavage and primary central nervous system (CNS) tumors
US7744888B2 (en) * 2001-08-03 2010-06-29 Abgenomics Cooperatief U.A. Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies
US20040116333A1 (en) 2001-08-03 2004-06-17 Rong-Hwa Lin Modulators of P-selectin glycoprotein ligand 1
MY148646A (en) 2004-05-10 2013-05-15 Abgenomics Cooperatief Ua Anti-psgl-1 antibodies
WO2005110456A2 (en) 2004-05-11 2005-11-24 Abgenomics Corporation T-cell death-inducing epitopes
US20130209449A9 (en) 2011-06-13 2013-08-15 Abgenomics Cooperatief U.A. Anti-psgl-1 antibodies and uses thereof

Also Published As

Publication number Publication date
JP5623690B2 (ja) 2014-11-12
ECSP067056A (es) 2007-01-26
EP2377889B1 (en) 2016-07-13
HK1102760A1 (en) 2007-12-07
US20110172397A1 (en) 2011-07-14
RU2482131C2 (ru) 2013-05-20
US20150183870A1 (en) 2015-07-02
CA2566305A1 (en) 2005-11-24
US8663641B2 (en) 2014-03-04
EP2377889A2 (en) 2011-10-19
NZ590690A (en) 2012-10-26
TWI448474B (zh) 2014-08-11
NO341844B1 (no) 2018-02-05
IL228033A0 (en) 2013-09-30
CN103980361B (zh) 2017-06-23
SG10201606541UA (en) 2016-09-29
TW200536860A (en) 2005-11-16
IL178838A0 (en) 2007-03-08
PH12015500247A1 (en) 2015-12-14
CN1984680B (zh) 2014-11-05
AU2005244072C1 (en) 2012-09-20
RU2006143686A (ru) 2008-06-20
EP2377890A3 (en) 2011-12-28
US9631019B2 (en) 2017-04-25
CA2907141A1 (en) 2005-11-24
AR048781A1 (es) 2006-05-24
NZ578647A (en) 2012-04-27
CN1984680A (zh) 2007-06-20
WO2005110475A2 (en) 2005-11-24
US20090191204A1 (en) 2009-07-30
MXPA06012986A (es) 2007-02-12
UA100356C2 (ru) 2012-12-25
PT1765396E (pt) 2014-02-25
UY28886A1 (es) 2005-12-30
US20170190782A1 (en) 2017-07-06
US10030075B2 (en) 2018-07-24
US8361472B2 (en) 2013-01-29
BRPI0510567B8 (pt) 2021-05-25
US20090198044A1 (en) 2009-08-06
TW201313740A (zh) 2013-04-01
EP1765396A2 (en) 2007-03-28
US20130101587A1 (en) 2013-04-25
MY148646A (en) 2013-05-15
TWI402274B (zh) 2013-07-21
BRPI0510567B1 (pt) 2018-11-13
EG26781A (en) 2014-09-07
US8828397B2 (en) 2014-09-09
EP2377889A3 (en) 2012-03-28
CN103980361A (zh) 2014-08-13
ES2448468T3 (es) 2014-03-14
EP2377890A2 (en) 2011-10-19
KR101256400B1 (ko) 2013-04-26
US8287871B2 (en) 2012-10-16
NO20065542L (no) 2007-01-31
KR20070020048A (ko) 2007-02-16
NZ551626A (en) 2010-03-26
US20050266003A1 (en) 2005-12-01
CA2812040C (en) 2016-05-03
US7604800B2 (en) 2009-10-20
JP2007536933A (ja) 2007-12-20
CA2907141C (en) 2016-05-31
EP1765396B1 (en) 2013-11-20
JP2011200247A (ja) 2011-10-13
BRPI0510567A (pt) 2007-11-20
SG187443A1 (en) 2013-02-28
AU2005244072B2 (en) 2012-05-31
JP2014223084A (ja) 2014-12-04
JP2014094010A (ja) 2014-05-22
CA2566305C (en) 2014-10-14
EP2377890B1 (en) 2016-08-10
IL228032A0 (en) 2013-09-30
CA2812040A1 (en) 2005-11-24
DK1765396T3 (en) 2014-02-24
WO2005110475A3 (en) 2006-02-23
ES2602633T3 (es) 2017-02-21
ES2598034T3 (es) 2017-01-24
EP1765396A4 (en) 2008-07-02
IL178838A (en) 2017-08-31
US20130102762A1 (en) 2013-04-25
AU2005244072A1 (en) 2005-11-24

Similar Documents

Publication Publication Date Title
PL1765396T3 (pl) Przeciwciała przeciwko PSGL-1
IL181575A0 (en) Anti-ox40l antibodies
TWI307630B (en) Immunoglobulins
IL179672A0 (en) Anti-cd3 antibodies
TWI365746B (en) Immunoglobulins
IL212350A0 (en) Anti-p-selectin antibodies
IL189580A0 (en) Anti-myostatin antibodies
IL189579A0 (en) Anti-myostatin antibodies
GB0420466D0 (en) Anti-glucan antibodies
GB0517487D0 (en) Antibodies
ZA200701952B (en) Anti-OX40L antibodies
HU0400305D0 (en) Set for spine-fixture
EP1780221A4 (en) ANTI-SYNOVIOLIN ANTIBODY
EP1896047A4 (en) ANTI-GFRALPHA3 ANTIBODIES
GB0505489D0 (en) Antibodies
GB0414799D0 (en) Immunoglobulins
GB0407197D0 (en) Immunoglobulins
GB0418415D0 (en) Antibody
GB0415644D0 (en) Monoclonal antibody
GB0420771D0 (en) Antibody
GB0402641D0 (en) Antibodies
GB0402642D0 (en) Antibodies
GB0512278D0 (en) Antibodies
GB0505054D0 (en) Antibodies
SI1951759T1 (sl) Protitelesa anti-EGFR